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Abstract 
Objective: To assess the clinical efficacy of regenerative periodontal surgery of intrabony 
defects using a combination of enamel matrix derivative (EMD) and bone graft compared 
with that of EMD alone.  
Materials and methods: The Cochrane Oral Health Group specialist trials, MEDLINE 
and EMBASE databases were searched for entries up to February 2014. The primary 
outcome was gain of clinical attachment (CAL). Weighted means and Forest plots were 
calculated for CAL gain, probing depth (PD) and gingival recession (REC). 
Results: Twelve studies reporting on 434 patients and 548 intrabony defects were 
selected for the analysis. Mean CAL gain amounted to 3.76 ± 1.07 mm (median 3.63 
95% CI: 3.51-3.75) following treatment with a combination of EMD and bone graft and to 
3.32±1.04 mm (median 3.40; 95% CI 3.28; 3.52) following treatment with EMD alone. 
Mean PD reduction measured 4.22±1.20 mm (median 4.10; 95%CI3.96-4.24) at sites 
treated with EMD and bone graft and yielded 4.12±1.07 mm (median 4.00; 95%CI 3.88-
4.12) at sites treated with EMD alone. Mean REC increase amounted to 0.76±0.42 mm 
(median 0.63; 95%CI 0.58-0.68) at sites treated with EMD and bone graft, and to 
0.91±0.26 mm (median 0.90; 95%CI0.87-0.93) at sites treated with EMD alone. 
Conclusions: Within their limits, the present results indicate that the combination of EMD 
and bone grafts may result in additional clinical improvements in terms of CAL gain and 
PD reduction compared with those obtained with EMD alone. The potential influence of 
the chosen graft material or of the surgical procedure (i.e. flap design) on the clinical 
outcomes is unclear. 
Clinical relevance: The present findings support the use of EMD and bone grafts for the 
treatment of intrabony periodontal defects. 
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Introduction 
Periodontitis is an infectious disease triggered by periodontal pathogenic bacteria and is 
characterized by pocket formation and attachment loss, ultimately affecting tooth survival 
[1]. Besides the anti-infectious therapy aiming to eliminate or reduce the periodontal 
pathogenic flora in order to arrest the destruction process, one important goal is to 
reconstruct the bone defects caused by the infectious process [2, 3].  During the last 
decades, various treatment modalities such as the use different bone grafting materials, 
guided tissue regeneration (GTR), enamel matrix derivative (EMD) or combinations 
thereof have been used to predictably regenerate the lost tooth`s supporting tissues 
including root cementum, periodontal ligament, alveolar bone and gingiva [2, 3].  
Narrative and systematic reviews have provided evidence indicating that the use of EMD 
in conjunction with open flap debridement (OFD) significantly improved the clinical 
outcomes in intrabony defects compared with OFD alone (OFD) [4-6]. In several studies 
[7-10] it was recognized that the morphology of the osseous defect plays an important 
role in the healing capacity of the defect itself. For example, in the presence of non-
contained defects, the use of a non-resorbable titanium-reinforced membrane or the 
combination of a resorbable membrane with a grafting material has been advocated [11]. 
Is has been also shown that the use of biomaterials without space-making properties 
such as EMD may not be sufficient for the treatment of deep non-contained intrabony 
defects. In fact, the results of a clinical study using EMD alone for the treatment of 
intrabony defects  [12] showed that three-walls defects yielded a 2.7x higher probability 
of gaining at least 3 mm of CAL compared with that of one-wall defects. In a randomized 
controlled clinical trial, the application of a non-resorbable titanium-reinforced membrane 
increased by 7x the probability of obtaining a significant CAL gain of at least 4 mm 
compared with the application of EMD alone in the treatment of non-contained intrabony 
defects [13]. Therefore, in order to maximize the clinical outcomes by stabilizing the 
blood clot and preventing flap collapse, the combination of EMD and bone grafts has 
been proposed [14, 15]. 
Results from a recent series of studies evaluating EMD adsorption to the surface of 
various types of bone grafts such as for example a demineralized bovine bone mineral 
(DBBM), have shown that this combination can stimulate the release of growth factors 
and cytokines including bone morphogenetic protein 2 and transforming growth factor 
beta 1. Moreover, there were significantly higher mRNA levels of osteoblast 
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differentiation markers including collagen1α1, alkaline phosphatase and osteocalcin in 
osteoblasts and PDL cells cultured on EMD-coated DBBM particles thus suggesting that 
EMD enhances osteoblast and PDL cell attachment, proliferation and differentiation on 
DBBM particles and provides a biologic rationale for using this combination in 
regenerative periodontal therapy [16]. Thus, the available clinical and biological data 
appear to support the combination of EMD and bone grafts for regenerative treatment in 
intrabony defects. It is also anticipated that this combination may even yield to synergistic 
effects where the graft material may act as an osteoconductive scaffold maintaining in 
the same time the defect space, while EMD may induce formation of root cementum, 
periodontal ligament and bone [14-16]. 
Despite the fact that in recent years, different combinations of EMD and bone grafts 
including autogenous bone [17-19], demineralized freeze dried bone allograft (DFDBA) 
[20-22], DBBM [23-30], and alloplastic materials [31-37] have been used to regenerate 
intrabony defects, the outcomes showed great variability. Thus, at the time being, it is still 
unclear to what extent the combination of EMD and different graft materials may lead to 
additional clinical improvements compared to the use of EMD alone. At present, 
according to the best of our knowledge, no data from systematic reviews including meta-
analysis are available and thus, the magnitude of the clinical improvements that can be 
obtained following the combination approach over the use of EMD alone is still unclear. 
Therefore, the aim of the present systematic review and meta-analysis was to assess the 
clinical efficacy of regenerative periodontal surgery in intrabony defects using a 
combination of enamel matrix derivative (EMD) and bone grafts compared with the 
application of EMD alone.  
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Materials and Methods 
This systematic review was prepared by following the recommendations by Needleman 
et al. [38] and the PRISMA principles (Preferred Reporting Items for Systematic Reviews 
and Meta-analysis) [39]. 
 
Focused question  
The focused question was formulated according to the Population Intervention Control 
Outcome (PICO) principle “In patients with intrabony defects, what are the clinical 
benefits of using a combination of enamel matrix derivative (EMD) and bone graft 
compared with EMD alone”. 
 
Search strategy 
The search was conducted on electronic databases up to February 2014. The search 
was applied to the Cochrane Oral Health Group specialist trials, MEDLINE and EMBASE. 
The strategy used was a combination of MeSH (Medical Subject Headings) terms and 
free text words: « surgical flaps » [MeSH] OR « periodontal pocket surgery » [MeSH] or 
« periodontal regeneration » [text words] OR « intra bony defect » [text word] OR 
« intrabony defect » [text word] OR « infra bony defect » [text word] OR « infrabony 
defect » [text word] OR « intra-bony defect » [text word] OR « intra osseus » [text word] 
OR « intraosseus » [text word] OR « intra-osseous » [text word] OR « amelogenin » [text 
word] OR « biological factor » [text word] OR « biological growth factor » [text word] OR 
« bone graft » [text word] OR « bone substitute » [text word] OR « autogenous bone » 
[text word] OR « deproteinized bovine bone mineral » [text word] OR « bone mineral » 
[text word] OR « xenograft » [text word] OR «emd» [text word] OR « EMD » [text word] 
OR « enamel matrix protein » [text word] OR « enamel protein » [text word] OR « dental 
enamel protein » [text word] OR « enamel matrix derivative » [text word] « alloplastic » [ 
text word] OR « allogenic » [text word] OR « longitudinal study » [MeSH] OR 
« randomized controlled study [MeSH] OR « controlled study » [MeSH] OR 
« comparative study [MeSH] OR « clinical trial » [MeSH] « combination therapy AND 
intrabony defect » [text word] « combination therapy AND intrabony defects » [text word].  
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Hand search included a search of Journal of Clinical Periodontology, Journal of 
Periodontology, Journal of Periodontal Research, International Journal of Periodontics 
and Restorative Dentistry and Clinical Oral Investigations. 
 
Inclusion Criteria 
The studies were included on the basis of the following criteria: 
• English language 
• Randomized Clinical Trials (RCT) comparing EMD + bone graft with 
EMD alone 
• Controlled Clinical Trials (CCT) comparing EMD + bone graft with 
EMD alone 
• Studies with a mean follow-up period between 6 and 24 months 
• Defect sites with Pocket Depth (PD) ≥ 5 mm 
• Intrabony defect depth ≥ 3 mm 
 
Exclusion Criteria 
• Studies based on questionnaire or interview 
• Radiographic studies 
• Studies with only histological data 
• Studies on furcation defects 
• Studies on supra-osseous defects 
• RCT or CCT comparing EMD + Bone Graft with Open Flap 
Debridement (OFD) 
• RCT or CCT comparing EMD + Bone Graft with Guided Tissue 
Regeneration (GTR)  
• RCT or CCT comparing EMD+Bone graft with Bone graft alone 
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Data extraction and analysis 
The titles identified by the search, were screened independently by two reviewers (M.M. 
and V.I.S.). The abstract of all studies of possible relevance were obtained and screened 
independently by the reviewers. When studies met the inclusion criteria or when 
insufficient data from abstracts were available to evaluate inclusion criteria, the full-text 
article was obtained. The selected papers were screened independently by the reviewers 
to confirm whether they met the inclusion criteria or not. The inter-examiner agreement 
was analyzed by kappa coefficient. Any discrepancy between the two reviewers was 
resolved via discussion. Data were extracted independently by the two examiners (M.M 
and V.I.S.). If the reviewers had data-related questions, the authors of the selected 
papers were contacted.  
 
Outcome measures 
The primary outcome measure (i.e. true end-point outcome) included: 
• Change in clinical attachment level (CAL) 
The secondary outcome measures (i.e. surrogate end-point outcomes) included: 
• Change in probing depth (PD) 
•  Change in gingival recession (REC)  
 
Methodological quality assessment  
With respect to randomized controlled trials (RCTs) and controlled clinical trials (CCTs), 
quality assessment was performed by means of the Cochrane Collaboration’s tool for 
assessing risk of bias (www.cochrane-handbook.org).  
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Data analysis 
Study outcomes are reported by means of evidence tables and a quantitative synthesis 
by means of a meta-analysis. 
For data analysis, EpiDat software (EpiDat version 3.1 for Windows, Dirección Xeral de 
Innovación e Xestión da Saúde Pública de Galicia - SPAIN) was used. Mean differences 
and 95% Confidence Intervals of differences (95%CI) were calculated for PD, CAL and 
REC. Statistical heterogeneity was evaluated by DerSimonian-Laird´s test, where p 
values below 0.05 were considered heterogeneous. The degree of inconsistency was 
verified by the I^2 test. An analysis by sub-groups was performed considering the 
different grafts associated with EMD using the random effects model due to the 
heterogeneity detected. The Forest plot was utilized to illustrated the weighted mean of 
the outcome in each study and the final estimate. 
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Results 
From an original yield of 12.288 titles and 152 abstracts, 15 studies were selected for the 
full-text analysis. Three studies were excluded and a total of 12 studies were selected for 
the analysis (Fig.1). Reasons for exclusion are summarized in Table 1. One study [35] 
was excluded because it reported only 6 months results and the same data were used in 
another publication with a follow-up of 1 year [36]. Two studies [33, 37] were excluded 
because an observation time of 4 years was reported.  
Study characteristics 
The summary of quality assessment was described in Table 2. In the randomized 
controlled clinical trials four studies [19, 23, 26, 34] had a high risk of bias.   
Descriptive data relative to the included twelve studies are reported in Table 3. Only one 
study was not specifically designed to test the combination of EMD and bone graft 
compared with EMD alone [30] whereas for the other studies, data were extracted from 
the original samples. All studies were randomized controlled clinical trials (RCTs). In ten 
studies a simple randomization was performed, whereas only in two studies [28, 30] a 
balanced block randomization was done. Eight studies were single-blinded [14,18, 26, 
28, 32, 34, 36], one was double blind [23], whereas in only one study the masking was 
not performed [19] and in two studies these data were not available [30, 31]. In all studies 
a power calculation was performed with the exception of three studies [20, 23, 36]. Two 
studies were conducted in private practice [14, 30], whereas one study was conducted 
both in private practice and in university [28]. Outcomes of other studies were not 
reported. Six different types of intervention were tested: in four studies a combination of 
EMD and DBBM was analyzed [23, 26, 28, 30], two studies were conducted using a 
combination of EMD and autologous bone graft [18,19], while two studies tested a 
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combination of EMD and Bioglass [31, 32]. A combination of hydroxyapatite and β-
tricalcium phosphate (HA + β-TCP) was used in two publications [14, 36]. The 
combination of EMD and DFDBA was tested in two studies [20, 21] while that of EMD 
and β-TCP was evaluated in one study [34]. The follow-up period varied between the 
studies (i.e., 6 months in two studies [20, 23], from 6 to 8 months in one study [26], 8 
months in one study [32], 12 months in seven studies [18, 19, 28, 30, 31, 34, 36] 24 
months in one study [14].  
 
Patient’s characteristics 
The studies reported a total of 434 patients (189 males and 245 females) with an age 
range between 19 and 76 years. Sixty-eight patients were tobacco smokers. Only one 
paper did not report smoking habits [20]. Five drop-outs were reported in three studies 
[14, 34, 36]. Patients enrolled in four studies suffered from chronic periodontitis [18, 28, 
32, 36], whereas in one study patients suffering from chronic and aggressive periodontitis 
[19] and in another study periodontitis was defined as moderate to advanced [26]. The 
other paper did not report about periodontal status (Tab.4). 
 
Tooth and defect characteristics at baseline 
The studies reported a total of 548 teeth with different morphology of intrabony defects 
(one defect per tooth). In four papers 1,2,3 walls intrabony defects were treated [20, 30, 
31, 34], whereas in three publications 2- and 3-wall defects were selected [18, 23, 26]. 
Four studies focused on 1-2 wall defects [14, 19, 32, 36]. In only one study the data 
about defect morphology was not available [28]. The percentage of sites with BoP+ was 
recorded only in three publications [18, 31, 34] (Tab.5).  
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Clinical and intra-surgical characteristics of defects at baseline 
Table 6 illustrates baseline characteristics of the included defects, surgical approach 
performed and the use of systemic antibiotics. At baseline mean PD was 8.18±2.86 
(median 7.74; 95%CI 6.86-8.62), mean CAL was 9.95±3.16 (median 9.80; 95%CI 8.45-
11.15) and mean REC was 1.53±1.24 (median 1.10 ; 95%CI 0.95-1.25) for intrabony 
defects treated with a combination of EMD and bone graft. The sites treated with EMD 
alone showed a mean PD, CAL and REC of 9.09±2.86 (median 8.20 ; 95%CI 7.26-9.14), 
10.90±3.17 (median 10.10 ; 95%CI 8.71-11.49) and 2.96±1.29 (median 1.10 ; 95%CI 
0.95-1.25) respectively. All studies reported PD values at baseline, whereas in three 
studies CAL and REC were not available [23, 26, 32]. During the surgical phases the 
mean distances CEJ-BD and INFRA were 9.38±3.08 (median 6.70; 95%CI 5.21-8.19) 
and 5.50±2.35 (median 5.20; 95%CI 4.40-6.00) respectively at sites treated with a 
combination of EMD and bone graft, while intrabony defects treated with EMD alone 
showed a mean CEJ-BD of 9.48±3.10 (median 6.80 ; 95%CI 5.29-8.31) and INFRA of 
5.52±2.36 (median  4.90 ; 95%CI 4.15-5.65). The mean CEJ-BD was reported in four 
studies [14, 19, 30, 31]. Only four studies did not record INFRA [23, 26, 34, 36]. In four 
studies a conventional flap with papilla preservation technique (MPPT or SPPT) was 
made [14, 19, 28, 36]. Microsurgical approaches with papilla preservation technique were 
performed in two studies [30, 34] while in five studies the surgical flap was elevated 
without papilla preservation technique [20, 23, 26, 31, 32]. In one study data about the 
use of papilla preservation technique was not available [18]. Systemic antibiotics were 
not prescribed in one study [30], whereas in two papers these data were not reported [31, 
36] (Tab.6).  
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Changes in BOP, PD, CAL, REC 
In table 7 clinical changes in terms of BOP, PD, CAL and REC changes are summarized.  
According to the results of the meta-analysis with inclusion of the 12 studies, high 
statistical heterogeneity was detected in the analysis of PD, CAL and REC (p<0.00001 
I^2=41,62%; p<0.00001 I^2=39,16%; p<0.00001 I^2=31,96% respectively). The 
percentage of sites with BoP+, were collected in 3 studies [18, 34, 36]. Forest plots of PD 
change are depicted in Fig.2. Mean PD reduction was 4.22±1.20 mm (median 4.10; 95% 
CI 3.96-4.24) at sites treated with EMD and bone graft and 4.12±1.07 mm (median 4.00; 
95% CI 3.88-4.12) at sites treated with EMD alone.  Mean difference of 0.05 mm (CI 95% 
-0.12-0.21) was calculated. The forest plot depicted in Fig. 3 illustrates the CAL gain after 
surgical interventions. Mean CAL gain was 3.76±1.07 mm (median 3.63 ; 95%CI 3.51-
3.75) for the intrabony defects treated with combination of EMD and bone graft, and  
3.32±1.04 mm (median 3.40 ; 95%CI 3.28-3.52) for the defects treated with EMD alone. 
Mean difference of 0.37 mm (CI 95% 0.20-0.54) was noted. The forest plot in Fig. 4 
demonstrates the REC increase at teeth treated with either EMD alone or with the 
combination approach. At sites treated with EMD and bone graft a mean REC increase of 
0.76±0.42 mm (median 0.63; 95%CI 0.58-0.68) was recorded, while at sites treated with 
EMD alone the mean REC increase amounted to 0.91±0.26 mm (median 0.90 ; 95%CI 
0.87-0.93). Mean difference measured 0.35 mm (CI 95% -0.52-0.19).  
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Tooth survival rates and complications 
Survival rate and complications are presented in table 8. No tooth was lost during the 
follow-up and the survival rate was 100%. In eight studies flap dehiscences were not 
noted [20, 23, 26, 28, 30, 31, 32, 34], whereas in the other studies these data are not 
available for the analysis. Only three studies reported data about primary wound healing 
of interdental space [14, 30, 34]. The outcomes related to the number of residual pocket 
depth ≥ 5 mm are not available for the analysis. In one study one site with attachment 
loss was recorded [31], while no attachment loss was noted in three publications  [19, 30, 
34]. These data were not available for analysis in the other studies. 
 
Discussion 
The present systematic review has evaluated the efficacy of combining EMD and bone 
grafts compared with the use of EMD alone in the treatment of periodontal intrabony 
based on existing RCTs. The outcomes indicate that treatment of periodontal intrabony 
defects using a combination of EMD and bone grafts appears to represent a predictable 
treatment modality. Unfortunately, there are few well-designed clinical studies evaluating 
the efficacy of these regenerative surgical protocols. The primary outcome variable 
selected was the CAL change after a mean follow-up period varying from 6 to 24 months. 
The evaluation period of 6 to 24 months was selected, due to the fact that this is the time 
frame used in the most clinical studies to evaluate the outcomes of reconstructive 
periodontal surgery.  
The findings from the meta-analysis have demonstrated significantly better CAL gain and 
PD reduction in the defects treated with EMD and bone grafts when compared with the 
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healing of the defects treated using EMD alone. Hence, the outcomes from the meta-
analysis suggest that the use of EMD with bone graft improve better results in terms of 
CAL gain and PD reduction. These data are in agreement with a recent narrative review, 
which has assessed the biologic rationale and potential clinical benefit of a combination 
EMD and bone grafts in the treatment of deep intrabony defects [40]. The authors 
concluded that although a clinical benefit of the combination approach was observed, 
direct evidence supporting this concept is still missing and further controlled clinical trials 
are required to explain the large variability that exists amongst the selected studies. 
However, the results of the present systematic review must be interpreted with caution. 
First of all, it should be kept in mind that in this meta-analysis, the outcomes of 
regenerative surgery performed in defects with different types of morphology (i.e. 1, -2 -3 
walled and combinations thereof), using different types of grafts and surgical techniques 
have been combined. Secondly, the lack of consistency and standardization may have 
contributed to the high heterogeneity of the results. Furthermore, due to the lack of data, 
no meta-analysis could be performed on defect morphology and surgical flap designs, 
which are well known factors influencing the outcomes following regenerative therapy 
[11, 12]. In many studies selected for the final analysis, the data about the management 
of interdental papilla and the primary would closure during early wound healing was not 
reported. While in most studies a conventional flap was performed, in two studies [30, 34] 
a minimally surgical approach was used. Those two studies reported CAL gains of 
4.0±1.0 mm and 3.7±1.3 mm respectively, but the micro-surgical approach did not seem 
to influence the healing. Interestingly, the data reported in these two studies are in 
agreement with the outcomes reported in the other studies included in the present meta-
analysis.  
Despite the fact that tooth survival rate was 100% using both regenerative approaches, 
none of the studies reported on the outcomes in terms of residual pockets ≥ 5 mm. 
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Furthermore, in most studies, no data on sites with attachment loss following 
regenerative surgery were recorded. In three papers [19, 30, 34] no sites with attachment 
loss were recorded, while only one paper mentioned [31] one site with attachment loss.  
An interesting finding of the present meta-analysis was the statistically significantly better 
outcome in terms of REC increase following treatment with EMD alone. While the 
biological or clinical background for this finding is a matter of speculation, the 
heterogeneity of surgical techniques and defects may serve as explanation.  
 
Conclusion  
Within their limits, the present results indicate that the combination of EMD and bone 
grafts may result in additional clinical improvements in terms of CAL gain and PD 
reduction compared with those obtained with EMD alone. The potential influence of the 
chosen graft material or of the surgical procedure (i.e. flap design) on the clinical 
outcomes is unclear. 
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Tab.1 Studies excluded at full-text analysis 
 
 
Study Reason for exclusion 
Jepsen et al 2008 (35) Same data of Meyle et al 2011  
Pietruska et al 2012 (37) Four years of follow-up  
Sculean et al 2007 (33) Four years of follow-up  
 
 
Tab.2 Cochrane Collaboration’s tool for assessing risk of bias 
 
 
STUDY 
Adequate 
sequence 
generation 
Allocation 
Concealment  Blinding 
Incomplete data 
addressed 
Free of  
selective 
reporting 
Free of 
other bias 
% of yes 
answers 
Lekovic et al. 
2000 (23) Yes Unclear Yes Unclear Unclear Yes 50 % 
Velasquez-Plata 
et al. 2002 (26) Yes NA Yes Unclear No Yes 50 % 
Zucchelli et al. 
2003 (28) Yes Yes Yes Unclear Yes Yes 83.3 % 
Gurinsky et al. 
2004 (20) Yes Unclear Yes Yes Unclear Yes 66.6 % 
Sculean et al. 
2005 (31) Yes Unclear Unclear Yes Yes Yes 66.6 % 
Bokan et al. 2006 
(34) Yes Yes Yes Unclear Unclear Unclear 50 % 
Kuru et al. 2006 
(32) Yes Unclear Yes Yes Yes Yes 83.3 % 
Guida et al. 2007 
(19) Yes NA No Yes No Yes 50 % 
Yilmaz et al. 
2010 (18) No No Yes Yes Yes Yes 66.6 % 
Meyle et al. 2011 
(36) Yes Yes Yes Yes Yes Yes 100 % 
Cortellini & 
Tonetti 2011 (30) Yes Yes Unclear Yes Yes Yes 83.3 % 
De Leonardis & 
Paolantonio 
2013 (14) 
Yes Yes Yes Yes Yes Yes 100 % 
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Tab.3 Characteristics of included studies 
 
 
Author Stud
y 
desi
gn 
Randomizat
ion 
Masking Power 
calculat
ion 
Setting Intervention Follow-up  
Lekovic et al. 
2000 (23) 
RCT Simple double 
blind 
NO NA EMD vsEMD+DBBM 6 months 
Velasquez-
Plata et al. 
2002 (26) 
RCT Simple single 
blind 
YES NA EMD vsEMD+DBBM 6 to 8 months 
Zucchelli et 
al. 2003 (28) 
RCT Balanced 
Blocks 
single 
blind 
YES Univ/Private EMD vs EMD+DBBM 12-months 
Gurinsky et 
al. 2004 (20) 
RCT Simple single 
blind 
NO NA EMD vs EMD+DFDBA 6-months 
Sculean et al. 
2005 (31) 
mR
CT 
Simple NA YES NA EMD vs 
EMD+Bioglass 
12-months  
Bokan et al. 
2006 (34) 
RCT Simple single 
blind 
YES NA EMD vs EMD+SBG 12-months 
Kuru et al. 
2006 (32) 
RCT Simple single 
blind 
YES NA EMD vs 
EMD+Bioglass 
8-months 
Guida et al. 
2007 (19) 
RCT Simple None YES University EMD vs EMD+ABG 12-months 
Yilmaz et al. 
2010 (18)   
RCT Simple single-
blind 
YES University EMD vs EMD+ABG 12-months 
Meyle et al. 
2011 (36) 
mR
CT 
Simple Single-
blind 
NO NA EMD vs EMD+HA- 
βTCP 
12-months 
Cortellini & 
Tonetti 2011 
(30) 
RCT Balanced 
Blocks 
NA YES Private EMD vsEMD+DBBM 12-months 
De Leonardis 
& 
Paolantonio  
2013 (14) 
RCT Simple Single-
blind 
YES Private EMD vs EMD+HA- 
βTCP 
24-months   
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Tab. 4 Patient’s characteristics 
 
 
Author N° of patients 
Gender 
(M/F) 
Mean age of 
patients (years) 
Age range of 
patients (years) 
Tobacco 
Smoke 
drop-out 
(Y/N) 
Type of 
periodontitis 
Lekovic et al. 
2000 (23) 21 8(m) 13(f) 39±1 NA 12/9 NA 0 
Velasquez-
Plata et al. 
2002 (26) 
16 7(m) 9(f) NA 6-65 4/12 mod/adva 0 
Zucchelli et al. 
2003 (28) 60 
26(m) 
34(f) 46.2± 8.4 34-62 20/40 Chronic 0 
Gurinsky et al. 
2004 (20) 40 
17(m) 
23(f) NA 19-76 NA NA 0 
Sculean et al. 
2005 (31) 30 
14 (m) 
16(f) NA NA 0/30 NA 0 
Bokan et al. 
2006 (34) 38 
17(m) 
21(f) NA NA 9/29 NA 1                  
Kuru et al. 
2006 (32) 23 10(m)13(f) 44.7 32-58 3/20 Chronic 0 
Guida et al. 
2007 (19) 27 
13(m) 
14(f) 46.3± 8.7 30-65 4/23 Chronic/Ag. 0 
Yilmaz et al. 
2010 (18) 40 
24(m) 
16(f) NA 30-50 0/40 Chronic 0 
Meyle et al. 
2011 (36) 73 
23(m) 
50(f) 46.9 21.1-66.7 12 /61 Chronic 2            
Cortellini & 
Tonetti 2011 
(30) 
30 15(m) 15(f) NA NA 4/26 NA 0 
De Leonardis 
& Paolantonio 
2013 (14) 
36 15(m) 21(f) 45.3± 5.9 30-68 0/36 NA 2 
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Tab. 5 Teeth and defects characteristics at baseline 
 
 
Author N° of teeth Type tooth N° of  defects Type of  defects BOP+ (%)         
Lekovic et al. 2000 42 NA 42 2-3 wall NA 
Velasquez-Plata et al. 
2002 (26) 32 Anterior/posterior 32 2-3 wall NA 
Zucchelli et al. 2003 
(28) 60 Anterior/posterior 60 NA NA 
Gurinsky et al. 2004 
(20) 67 Anterior/posterior    34EMD 33(EMD+DFDBA) 1-2-3-wall NA                            
Sculean et al. 2005 
(31) 30 NA 30 1-2-3-wall 
50 EMD 
 52(EMD+BG)                                 
Bokan et al. 2006 (34) 38 Anterior/posterior                     38 1-2-3-wall 43 EMD  42 (EMD+SBG)                                 
Kuru et al. 2006 (32) NA NA 40 1-2 wall NA 
Guida et al. 2007 (19) 28 Anterior/posterior                         28 1-2 wall NA                           
Yilmaz et al. 2010 (18) 40 Anterior/posterior               40       2-3 wall 49 EMD  50(EMD+ABG) 
Meyle et al. 2011 (36) 73 NA 73 1-2 wall NA 
Cortellini & Tonetti 
2011 (30) 30                             NA 30 combination 1-2-3-wall NA 
De Leonardis & 
Paolantonio 2013 (14) 68 NA 68 1-2 wall NA 
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Tab.6 Clinical and Intra-surgical characteristic of defects at baseline 
 
 
Authors PD  
(mm) 
CAL 
(mm) 
REC 
(mm) 
CEJ-BD 
(mm) 
INFRA (mm) PPT 
(Y/N) 
MIST/CF  Antibio 
(Y/N) 
Lekovic et al. 
2000 
EMD(7.33±1.22 v) 
EMD+DBBM( 
7.74±1.41 v) 
(7.16 ±1.20 l) ( 
7.18±1.28 l) 
NA NA NA 
 
NA N CF Y 
Velasquez-
Prata et al. 2002 
(26) 
EMD( 6.6±1.3) 
EMD+DBBM( 6.9±0.9) 
NA NA NA NA N CF Y 
Zucchelli et al. 
2003 (28) 
EMD( 9.2±1.1) 
EMD+DBBM( 9.4±1.1) 
EMD( 10.1±1.4) 
EMD+DBBM( 
10.3±1.5) 
EMD( 0.9±0.9) 
EMD+DBBM( 
0.9±0.7) 
EMD( 11.7±1.7) 
EMD+DFDBA( 11.4±1.7) 
EMD( 6.8±0.9) 
EMD+DBBM( 6.7±1.0)  
Y SPPT CF Y 
Gurinsky et al. 
2004 (20) 
EMD( 7.5±0.3) 
EMD+DFDBA( 
7.5±0.3) 
EMD( 8.1±0.3) 
EMD+DFDBA( 
8.2±0.3) 
EMD( 0.6±0.0) 
EMD+DFDBA( 
0.7±0.0) 
NA EMD( 4.9±0.3) 
EMD+DFDBA( 5.2±0.3)  
N CF NA 
Sculean et al. 
2005 (31) 
EMD( 8.5±1.5) 
EMD+BG ( 8.5±1.1) 
EMD( 10.2±2.1) 
EMD+BG ( 10.4±1.5) 
EMD( 1.5±1.4) 
EMD+BG ( 1.9±1.1) 
EMD( 11.2±1.4) 
EMD+BG( 11.3±1.3 
EMD( 4.1±1.1)  
EMD+BG( 4.3±1.0) 
N CF Y 
Bokan et al. 
2006 (34) 
EMD( 8.6±1.3) 
EMD+SBG( 8.6±1.4) 
EMD( 10.3±1.8) 
EMD+ SBG ( 
9.8±1.3) 
EMD( 2.4±2.0) 
EMD+ SBG ( 
1.3±1.2) 
 
NA 
 
 
NA       SPPT             
  
MIST 
 
Y 
Kuru et al. 2006 
(32) 
EMD( 9.47±0.81) 
EMD+BG( 9.77±0.01) 
NA NA NA EMD( 5.68±0.59) 
EMD+BG( 5.48±0.62) 
N CF Y 
Guida et al. 
2007 (19) 
EMD( 9.6±1.7) 
EMD+ABG( 9.1±1.6) 
EMD( 10.6±1.3) 
EMD+ABG( 
10.3±1.5) 
EMD( 1.1±1.0) 
EMD+ABG( 1.1±0.9) 
EMD( 11.7±1.7) 
EMD+ABG(10.9±2.0) 
 
 
EMD( 6.2±2.0) 
EMD+ABG(7.0±1.2) 
 
MPPT CF Y 
Yilmaz et al. 
2010 (18) 
EMD( 8.2±0.7) 
EMD+ABG( 8.4±1.2) 
EMD( 11.3±0.9) 
EMD+ABG( 
11.7±1.0) 
EMD( 3.1±1.1) 
EMD+ABG( 3.3±1.5) 
NA EMD( 5.2±0.7) 
EMD+ABG(5.4±1.0) 
 
 
NA CF Y 
Meyle et al. 
2011 (36) 
EMD( 7.1±1.5) 
EMD+HA+β TCP( 
6.9±1.8) 
EMD( 10.1±2.2) 
EMD+HA+β TCP( 
9.3±2.1) 
EMD( 3.0±1.6) 
EMD+HA+β TCP( 
2.4±1.3) 
NA NA SPPT CF NA 
Cortellini & 
Tonetti 2011 
(30) 
EMD( 7.8±0.9) 
EMD+DBBM( 7.3±1.2) 
 
EMD( 9.9±1.3) 
EMD+DBBM( 
10.1±2.4) 
EMD( 2.1±1.4) 
EMD+DBBM( 
2.9±1.8) 
 
EMD( 10.5±1.5) 
EMD+DBBM( 10.9±2.2) 
 
EMD(        5.3±1.0) 
EMD+DBBM( 5.2±1.4) 
Y MIST N 
De Leonardis & 
Paolantonio 
2013 (14) 
EMD+HbTC( 8.8±1.0) 
EMD( 8.7±1.0) 
EMD+HbTC( 
9.4±1.1) 
EMD( 9.2±1.0) 
EMD+HbTC( 
0.6±0.4) 
EMD( 0.5±0.4) 
EMD+HbTC( 6.7±1.0) 
EMD( 6.8±0.9) 
EMD+HbTC( 4.5±1.8) 
EMD( 5.2±1.4) 
M/S CF Y 
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Tab. 7 Changes in BOP, PD, CAL and REC 
 
 
Authors BOP (%) PD change (mm) CAL change (mm) REC change (mm) 
Lekovic et al. 
2000 (23) NA EMD (1.91±1.42v) EMD+DBBM (3.43±1.32v) EMD (1.72±1.33v) EMD+DBBM (3.13±1.41v) EMD (1.26±1.34v) EMD+DBBM (1.31±1.26v) EMD (1.85±1.38l) 
EMD+DBBM (3.36±1.135 l) 
EMD (1.75±1.37l) 
EMD+DBBM (3.11±1.39 l) 
EMD (1.22±1.28l) 
EMD+DBBM (1.29±1.24l) 
Velasquez-Plata 
et al. 2002 (26) NA EMD (3.8±1.2) EMD+DBBM (4.0±0.8)                        EMD (2.9±0.9) EMD+DBBM(3.4±0.9)        EMD (0.8±0.8) EMD+DBBM (0.3±0.6) 
Zucchelli et al. 
2003 (28) NA EMD (5.8±0.8) EMD+DBBM (6.2±0.4)               EMD (4.9±1.0) EMD+DBBM (5.8±1.1)                  EMD (0.9±0.5) EMD+DBBM (0.4±0.6)  
Gurinsky et al. 
2004 (20) NA EMD (4.0±0.3) EMD+FDBA (3.6±0.2)                   EMD (3.2±0.3) EMD+FDBA (3.0±0.3)                   EMD (0.7±0.2) EMD+FDBA(0.5±0.3)             
Sculean et al. 
2005 (31) 
EMD(22); 
EMD+BG(28) 
EMD (4.5±2.0) EMD+BG 
(4.2±1.4)                                          
EMD (3.9±1.8) EMD+BG 
(3.2±1.7) 
EMD (0.9±0.7) EMD+BG 
(1.1±0.8) 
Bokan et al. 2006 
(34) 
EMD(25); 
EMD+SBG(21) 
EMD (3.9±1.3) 
EMD+SBG(4.1±1.2)                                        
EMD (3.7±1.0) EMD+ 
SBG(4.0±1.0) 
EMD (0.7±1.3) EMD+ SBG 
(0.7±1.1) 
Kuru et al. 2006 
(32) NA EMD (5.03±0.89) EMD+BG (5.73±0.80)                           EMD (4.06±1.06) EMD+BG (5.17±0.85) EMD (0.97±0.24) EMD+BG (0.56±0.18) 
Guida et al. 2007 
(19) NA EMD (5.6±1.7) EMD+ABG (5.1±1.7)                                          EMD (4.6±1.3) EMD+ABG (4.9±1.8)  EMD (1.1±0.7) EMD+ABG (0.3±0.8) 
Yilmaz et al. 2010 
(18) 
EMD(16); 
EMD+ABG(15) EMD (4.6±0.4) EMD+ABG (5.6±0.9)                                      EMD (3.4±0.8) EMD+ABG (4.2±1.1) EMD (1.2±0.8) EMD+ABG (1.4±0.9) 
Meyle et al. 2011 
(36) NA EMD (2.9±1.8) EMD+HA- βTCP (2.8±2.1)                EMD (1.69±2.1) EMD+HA- βTCP (1.9±1.7) EMD (0.97±1.1) EMD+HA- βTCP (1.11±1.3) 
Cortellini & 
Tonetti 2011 (30) NA EMD (4.4±1.2) EMD+DBBM (4.0±1.3)                                  EMD (4.1±1.2) EMD+DBBM (3.7±1.3) EMD (0.3±0.5) EMD+DBBM (0.3±0.7) 
De Leonardis & 
Paolantonio 2013 
(14) 
NA EMD (3.7±0.7) EMD+HbTC (4.2±0.6)                                      EMD (2.9±0.7) EMD+HbTC (3.6±0.9) EMD (0.8±0.4) EMD+HbTC (0.6±0.4) 
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Tab.8 Survival rate and complications 
 
Authors Tooth loss 
Survival 
Rate 
Flap 
dehiscences  
Primary would healing of 
interdental space  
N° of residual 
pockets ≥ 5 mm 
N° of sites 
with CAL loss 
Lekovic et al. 
2000 (23) 0 100% 0 NA NA NA 
Velasquez-
Plata et al. 2002 
(26) 
0 100% 0 NA NA NA 
Zucchelli et al. 
2003 (28) 0 100% 0 NA NA NA 
Gurinsky et al. 
2004 (20) 0 100% 0 NA NA NA 
Sculean et al. 
2005 (31) 0 100% 0 NA NA 1 
Bokan et al. 
2006 (34) 0 100% 0 Yes NA 0 
Kuru et al. 2006 
(32) 0 100% 0 NA NA NA 
Guida et al. 
2007 (19) 0 100% NA NA NA 0 
Yilmaz et al. 
2010 (18) 0 100% NA NA NA NA 
Meyle et al. 
2011 (36) 0 100% NA NA NA NA 
Cortellini & 
Tonetti 2011 
(30) 
0 100% 0 29/30 NA 0 
De Leonardis & 
Paolantonio 
2013 (14) 
0 100% NA Yes NA  NA 
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Footnotes 
 
NA : not available 
EMD : enamel matrix derivative 
DFDBA : demineralized freeze-dried bone allograft 
ABG : Autogenous bone graft 
SBG: Silicate bone graft 
HA- βTCP:hydroxyapatite and β-tricalcium phosphate 
DBBM: deproteinized bovine bone mineral 
RCT: Randomized clinical trial 
m-RCT: multicentre randomized clinical trial 
m : male 
f: female 
mod/adva: moderate/advanced 
Ag: aggressive 
BoP+ : bleeding on probing 
PD : probing depth 
CAL : clinical attachment level 
REC : gingival recession 
CEJ-BD : vertical distance from CEJ to bone defect 
INFRA : intrabony component 
PPT: papilla preservation technique 
MIST: Minimally invasive surgical technique 
CF: conventional flap 
SPPT: simplified papilla preservation technique 
MPPT: modified papilla preservation technique 
Y: Yes 
N: No 
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Fig.1 Preferred reporting items for Systematic Reviews and Meta Analyses (PRISMA) flow diagram 
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Fig. 2 Forest plot from fixed effects of meta-analysis evaluating the differences in PD 
reduction (in mm) after surgical treatment using EMD and bone graft or EMD alone 
(weighted mean difference, 95% CI) 
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Fig.3 Forest plot from fixed effects of meta-analysis evaluating the differences in CAL 
gain (in mm) after surgical treatment using EMD and bone graft or EMD alone (weighted 
mean difference, 95% CI) 
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Fig.4 Forest plot from fixed effects of meta-analysis evaluating the differences in REC 
increase (in mm) after surgical treatment using EMD and bone graft or EMD alone 
(weighted mean difference, 95% CI) 
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